While Humira’s 2023 loss of exclusivity hung over AbbVie’s head for years, the ascent of the Chicago drugmaker’s immunology successors Skyrizi and Rinvoq under prior CEO Richard Gonzalez has swiftly ...
Record-breaking AbbVie results: AbbVie exceeded revenue forecasts with $61.2 billion in 2025 sales, driven by 8.6% growth despite significant Humira erosion. Shareholder vote outcomes: AbbVie ...
AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, ...
AbbVie made a change atop its board of directors, naming CEO Robert Michael as chairman on Friday morning. The pharma giant announced that Michael will succeed Richard A. Gonzalez, the former CEO of ...
Hosted on MSN
AbbVie CEO Sees ‘Substantial Momentum’ For Remaining Year After Q2 Earnings Beat: Retail’s No Longer Pessimistic
AbbVie (ABBV) CEO Robert A. Michael on Thursday said that the drug maker is entering the second half of the year with “substantial momentum” after it reported second-quarter earnings that surpassed ...
(RTTNews) - Biopharmaceutical company AbbVie, Inc. (ABBV) announced Friday that its board of directors has unanimously elected chief executive officer Robert Michael to assume the additional position ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results